Tokyo-based Atonarp raised $8 million in a round led by Walden Riverwood Ventures to further develop the company's smart spectrometer. Atonarp is developing a spectrometer that can non-invasively detect early phase cancer detection and it also has designed on non-invasive blood glucose measurement.
To detect cancer, the company's device analyzes a user's breath. Atonarp's website notes that...
